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ABSTRACT                                                                                                                                                                                                                 
Humoral and cellular mechanisms play roles in immune response to foreign antigens. The present study was designed to 
determine the T lymphocyte subsets (CD4 + T cells, CD8 + T cells and CD4/CD8 ratio) in the prostate cancer subjects and 
control subjects. CD4 + T cells (µl/count) and CD8 + T cells (µl/count) were estimated using flow cytometric method by Partec 
while CD4/CD8 ratio was calculated from the results obtained from the CD4 + T cells and CD8 + T cells. CD4 + T cells and CD8 
+ T cells decreased significantly while the CD4/CD8 ratio increased significantly in the prostate cancer subjects compared to the 
control subjects. The suppressed CD4 + and CD8 + T cell counts in prostate cancer subjects may indicate immune instability in 
the prostate cancer subjects. 
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RESUME 
Des mécanismes humoraux  et cellulaires jouent  un rôle dans la réponse immunitaire aux antigènes. La présente  étude a  
été conçue pour  déterminer  les  sous  – ensembles de lymphocyte  T (CD4 + cellules T, CD8  + cellules  T et le rapport CD4/CD8) 
dans les sujets atteints de cancer de la prostate et sujets témoins. CD4 + cellules T (µl/count) et CD8 + cellules T ont été estimées en 
utilisant la méthode de cytométrique en flux par Partec tandis que rapport CD4 /CD8 a été calculé à partir des résultats 
obtenus des CD4 + cellules  T et CD8 + cellules  T. Lymphocytes  T CD4  +  et CD8  +  ont diminué de manière significative tandis 
que le rapport CD4/CD8 a augmenté de manière significative chez les sujets atteints de cancer de la prostate par rapport aux sujets 
témoins. Les cellules T CD4 + et CD8+ supprimés comptent chez les sujets atteints de cancer de la prostate peut indiquer une 
instabilité immunitaire chez les sujets de cancer de la prostate. 
 
Mots clés :  Sous – ensembles  de lymphocytes  T,  cancer de la prostate, tumeur. 
 
INTRODUCTION                                                                                                                                                                                  
The incidence of prostate cancer in Nigeria is 18.2% 
and prostate cancer is about 9.6% of all mortality from 
cancer cases [1]. Both humoral and cellular 
mechanisms play roles in immune response to foreign 
antigens. Although, most humoral responses cannot 
prevent tumour growth, effector cells, such as T cells, 
macrophages, and natural killer cells have relatively 
effective tumouricidal abilities. Despite the activity of 
effector cells, host immunoreactivity may fail to 
control tumour occurrence and growth. Tumours  
 
develop when this immune surveillance breaks down
or is overwhelmed [2,3]. It has been stated that 
although many tumours are eliminated by the 
immune system (and thus are never detected), others 
continue to grow despite the presence of Tumour 
associated antigens [4]. Immune cells infiltrating 
human solid tumours have been extensively studied 
and found to exhibit unique phenotypic and 
functional characteristics [5,6]. Tumour-derived 
factors have been shown to induce death of immune 
cells at the tumour sites and in the peripheral 
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circulation [7]. The frequency of CD8+ T cells 
undergoing spontaneous apoptosis in the blood of 
patients with cancer was found to be significantly 
elevated relative to that in sex- or age-matched 
healthy controls [8]. CD8+ T cells were preferentially 
targeted for cell death compared to circulating CD4+ 
T cells [9]. It has long been recognized that disease 
progression in cancer patients is not solely 
determined by the characteristics of the tumour but 
also by the host response to foreign antigen [10]. 
The conversion of CD8+ T cells into suppressor cells 
may be one of the mechanisms by which tumours 
restrict the immune system’s ability to control tumour 
growth and that activated CD4+ T cells that enter 
tumours may secrete factors that support the CD8+ T 
cell anti tumour functions, or may help other immune 
cells located in the tumour block the processes by 
which CD8+ T cells acquire their suppressive activity 
[11]. 
The study therefore aimed to determine the levels of 
T lymphocyte subsets (CD4+ T cells and CD8+ T cells) 
in prostate cancer subjects since they play active roles 
in immune response against tumours. 
MATERIALS AND METHODS 
A total of fifty prostate cancer subjects were recruited 
using non probability consecutive sampling. All the 
subjects gave their consents after they were informed 
of the investigations to be carried out. Ethical 
clearance was also obtained from the ethical 
committee of the Nnamdi Azikiwe University 
Teaching Hospital, Nnewi, Anambra State. The mean 
age of the prostate cancer subjects was 69 ± 7. 
Thirteen subjects out of all the subjects were in stage 
1, twenty three were in stage 2 and fourteen were in 
stage 3. Twenty-nine out of all the subjects were on 
chemotherapy. The subjects who went through 
orchidectomy received Bicalutamide (Casodex) 
150mg once daily while the other prostate cancer 
subjects who did not go through orchidectomy 
received Goserelin (3.6mg) every 28 days and 
Casodex (50mg) once daily.  
A total of fifty apparently healthy males without any 
family history of cancer participated in the study. The 
mean age of the subjects was 52±13 years. They were 
recruited after they underwent digital rectal 
examination and no clinical tumour was observed. 
The subjects were apparently healthy subjects without 
any other diseased condition. 
Two milliliters of blood samples were collected from 
each subjects into Disodium ethylene diamine tetra 
acetic acid (EDTA) for the estimation of CD4 + and 
CD8 + T cells within 2 hours of collection using flow 
cytometric method[12].  
The Mean and Standard Deviation (SD) were 
calculated for each parameter using Statistical 
package for Social Sciences (SPSS version 17.0). 
Differences in the means for each parameter between 
the two groups were compared using Student’s t test 
and analysis of variance (ANOVA). 
RESULTS                                                                                                                                                                                                  
CD4 + T cells and CD8 + T cells in the prostate cancer 
subjects were significantly decreased (p<0.05) 
compared to the control subjects; while the CD4/CD8 
ratio in the prostate cancer subjects were significantly 
increased (Table 1).  
There was no significance difference in CD4 + T cells, 
CD8 + T cells and CD4/CD8 ratio based on stages 
and chemotherapy (Tables 2 and 3). 
 
TABLE 1: T LYMPHOCYTE SUBSETS IN PROSTATE CANCER 
Parameters Prostate cancer Control P value 
CD4+ T cells (µl/count) 696±86 1084±167 0.000* 
CD8 +T cells (µl/count) 391 ±51 666 ±100 0.000* 
CD4/CD8 Ratio 1.79± 0.19 1.65± 0.18 0000* 
*significant at p<0.05 
TABLE 2: T LYMPHOCYTE SUBSETS IN PROSTATE CANCER STAGES 
Parameters  Prostate cancer 
subjects in Stage 1 
 
N=13 
Prostate cancer subjects in 
Stage 2 
 
N=23 
Prostate cancer subjects in 
Stage 3 
 
N=14 
F-
values 
P-
values 
CD4+ T cells 
(µl/count) 
728 ± 111 689 ± 91 703 ± 73 0.353 0.704 
CD8 +T cells 
(µl/count) 
405 ± 16 393 ± 51 382 ± 57 0.346 0.709 
CD4/CD8 Ratio 1.79 ± 0.22 1.76 ± 0.17 1.86 ± 0.23 1.391 0.259 
 
 
181 
 
TABLE 3: T LYMPHOCYTE SUBSETS IN PROSTATE CANCER BASED ON CHEMOTHERAPY 
Parameters Prostate cancer subjects not on chemotherapy 
N=21 
 Prostate cancer subjects on chemotherapy 
N=29 
P-values 
CD4+ T cells (µl/count) 713  ± 90 683 ±83 0.238 
CD8 +T cells (µl/count) 399 ± 49 385 ± 53 0.351 
CD4/CD8 Ratio 1.80  ± 0.18471 1.79 ±0 .20 0.884 
 
DISCUSSION                                                                                                                                                                                              
In this study, there was significant decrease in the 
levels of the T lymphocyte subsets of prostate cancer 
subjects compared with the male control subjects. The 
decrease in the mean CD4 + T cells and CD8 + T cells 
are as a result of their involvement in the destruction 
of the tumour antigens. The decrease in the T 
lymphocyte subsets is in line with another work 
which similarly observed decreases in CD4 + T cells 
and CD8 + T cells of prostate cancer subjects [13]. T-
cell lymphocytes are important elements in the 
immune response and are regulated through a 
cascade of cellular and cytokine-based interactions. 
Furthermore, CD4+ lymphocytes, or T-helper cells, 
recognize antigens in conjunction with antigen 
presenting cells (APC) and produce cytokines that 
induce a wide response against foreign proteins on 
viruses or those on tumour cells [13]. The CD8 + T 
cells have direct tumouricidal activities that lead to 
the destruction of the tumour antigens [13,14,15]. 
These activities contribute to the significant increase 
recorded for the CD4/CD8 ratio in the prostate cancer 
subjects. However, it was reported that men with 
higher counts of CD4 + T cells in their prostate 
tumour environment have an increased risk of dying 
of prostate cancer [16]. The study did not observe any 
significant difference in the T lymphocyte subsets 
based on the stages of prostate cancer as well as the 
use of chemotherapy.  
Conclusion                                                                                                                             
Thus, the study concluded  that there were significant 
decreases in CD4 + T cells and CD8 + T cells of 
prostate cancer subjects compared with the control 
subjects while the CD4+ T cells / CD8+ T cells ratio 
was significantly raised showing immune instability 
in the cancer subjects 
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